ATE322507T1 - Verfahren zur herstellung eines monoklonalen antikörpers, ein monoklonaler antikörper, eine pharmazeutische zusammensetzung und ein diagnostisches reagenz - Google Patents

Verfahren zur herstellung eines monoklonalen antikörpers, ein monoklonaler antikörper, eine pharmazeutische zusammensetzung und ein diagnostisches reagenz

Info

Publication number
ATE322507T1
ATE322507T1 AT97203769T AT97203769T ATE322507T1 AT E322507 T1 ATE322507 T1 AT E322507T1 AT 97203769 T AT97203769 T AT 97203769T AT 97203769 T AT97203769 T AT 97203769T AT E322507 T1 ATE322507 T1 AT E322507T1
Authority
AT
Austria
Prior art keywords
monoclonal antibody
antigens
producing
cells
pharmaceutical composition
Prior art date
Application number
AT97203769T
Other languages
English (en)
Inventor
Petrus Gerardus A Steenbakkers
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE322507T1 publication Critical patent/ATE322507T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
AT97203769T 1996-12-06 1997-12-02 Verfahren zur herstellung eines monoklonalen antikörpers, ein monoklonaler antikörper, eine pharmazeutische zusammensetzung und ein diagnostisches reagenz ATE322507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96203465 1996-12-06
EP97201972 1997-06-27

Publications (1)

Publication Number Publication Date
ATE322507T1 true ATE322507T1 (de) 2006-04-15

Family

ID=26143410

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97203769T ATE322507T1 (de) 1996-12-06 1997-12-02 Verfahren zur herstellung eines monoklonalen antikörpers, ein monoklonaler antikörper, eine pharmazeutische zusammensetzung und ein diagnostisches reagenz

Country Status (17)

Country Link
US (3) US6020170A (de)
EP (1) EP0856520B1 (de)
JP (1) JPH10179160A (de)
KR (1) KR100543053B1 (de)
AT (1) ATE322507T1 (de)
AU (1) AU733165B2 (de)
BR (1) BR9706236A (de)
CA (1) CA2221682C (de)
DE (1) DE69735621T2 (de)
DK (1) DK0856520T3 (de)
ES (1) ES2262170T3 (de)
HU (1) HUP9702359A3 (de)
IL (1) IL122233A (de)
NO (1) NO327047B1 (de)
NZ (1) NZ329314A (de)
PL (1) PL193821B1 (de)
PT (1) PT856520E (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037503A1 (en) * 1998-12-22 2000-06-29 Raven Biotechnologies, Inc. Compositions and methods for generating monoclonal antibodies representative of a specific cell type
SE9902817D0 (sv) 1999-07-30 1999-07-30 A & Science Invest Ab A method for selective electrofusion of at least two fusion partners having cell-like membranes
CA2386398A1 (en) * 1999-10-18 2001-04-26 Akzo Nobel Nv Modified peptides and peptidomimetics for use in immunotherapy
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
EP1319184B1 (de) 2000-08-14 2007-07-25 N.V. Organon Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
JP2006508014A (ja) * 2001-07-24 2006-03-09 イエール・ユニバーシテイ キチナーゼおよびキチナーゼ様分子、ならびに炎症性疾患に関する方法、組成物およびキット
US7018819B2 (en) * 2001-11-30 2006-03-28 Cellectricon Ab Method and apparatus for manipulation of cells and cell-like structures focused electric fields in microfludic systems and use thereof
KR20060002879A (ko) * 2003-03-28 2006-01-09 자이단호진 토야마켄 신세키 산교기코 1개의 항원 특이적 ｂ림프구를 이용한 항원 특이적 항체를생산하는 하이브리도마의 제조방법 및 단일 클론 항체의제조방법
EP2272566A3 (de) 2003-08-18 2013-01-02 MedImmune, LLC Humanisierung von antikörpern
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1729805A4 (de) * 2004-02-25 2008-11-26 Medimmune Inc Verfahren und zusammensetzungen im zusammenhang mit chitinasen und chitinase-artigen molekülen und modulierung von osteoklasten
AU2005325801A1 (en) * 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
EP2240108B1 (de) * 2008-01-09 2015-04-29 Alcon LenSx, Inc. Gewebefragmentierung mit laser-photodisruption
US20160075766A1 (en) * 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
WO2019105864A1 (en) 2017-11-30 2019-06-06 F. Hoffmann-La Roche Ag B-cell cultivation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
EP0255547A1 (de) * 1986-07-29 1988-02-10 Kishimoto, Tadamitsu, Prof. Monoklonale Antikörper spezifisch gegen Oberflächen-IgE-Rezeptor, sowie Hybrid-Zellinien zur Herstellung und Verwendung dieser Antikörper
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
US5473051A (en) * 1990-07-19 1995-12-05 The Scripps Research Institute Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs
DK0488470T3 (da) * 1990-11-26 1997-12-22 Akzo Nobel Nv Fremgangsmåde til fremstilling af antistoffer
NZ331688A (en) * 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins

Also Published As

Publication number Publication date
NO975714L (no) 1998-06-08
CA2221682A1 (en) 1998-06-06
PT856520E (pt) 2006-08-31
EP0856520A1 (de) 1998-08-05
HUP9702359A2 (hu) 1998-09-28
AU733165B2 (en) 2001-05-10
IL122233A0 (en) 1998-04-05
EP0856520B1 (de) 2006-04-05
NO975714D0 (no) 1997-12-05
NZ329314A (en) 1999-02-25
JPH10179160A (ja) 1998-07-07
HU9702359D0 (en) 1998-03-02
KR19980063909A (ko) 1998-10-07
US6020170A (en) 2000-02-01
ES2262170T3 (es) 2006-11-16
MX9709446A (es) 1998-07-31
DK0856520T3 (da) 2006-07-31
NO327047B1 (no) 2009-04-14
KR100543053B1 (ko) 2006-06-13
DE69735621T2 (de) 2006-08-24
IL122233A (en) 2001-04-30
AU4690897A (en) 1998-06-11
PL323572A1 (en) 1998-06-08
PL193821B1 (pl) 2007-03-30
HUP9702359A3 (en) 2001-11-28
DE69735621D1 (de) 2006-05-18
BR9706236A (pt) 1999-05-04
US20020143150A1 (en) 2002-10-03
US6392020B1 (en) 2002-05-21
CA2221682C (en) 2011-10-18

Similar Documents

Publication Publication Date Title
DE69735621D1 (de) Verfahren zur Herstellung eines monoklonalen Antikörpers, ein monoklonaler Antikörper, eine pharmazeutische Zusammensetzung und ein diagnostisches Reagenz
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
ATE346303T1 (de) Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden
ATE145007T1 (de) Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
AU648591B2 (en) Hydrophilic polypeptide spacer
DK0994728T3 (da) Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
WO1995018826A3 (en) Purified primate ctla-8 antigens and related reagents
ATE196607T1 (de) Verfahren zur ex vivo-immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer antikörper
ATE123780T1 (de) Verfahren zur verwendung und herstellung von peptiden.
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE69840448D1 (de) 13c,15n,2h markierte proteine zur nmr strukturbestimmung und deren herstellung
EP0770679A3 (de) HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
ATE230020T1 (de) Katalytische antikörperkomponente
WO1992010514A3 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
ATE328611T1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene,daraus entwickelte impfstoffe sowie deren verwendung
DE3485054D1 (de) Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung.
DE3783002D1 (de) Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega.
DE69332637D1 (de) Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
RU2000127463A (ru) Способ качественного определения гомеопатического лекарственного препарата или потенцированной формы вещества
DE3787121D1 (de) Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen.
DE59005082D1 (de) Antikörper gegen hochkonservierte Aminosäuresequenzen von immunogenen Substanzen, Verfahren zur Herstellung dieser Antikörper, sowie deren Verwendung in Immunoassays.
FI970299A0 (fi) Oligomeeriset kantajamolekyylit, joissa on määritetysti sisällytettyjä merkitsinryhmiä ja hapteeneja
DD295167A1 (de) Verfahren zur herstellung monoklonaler antikoerper gegen spermaspezifische antigene im molekulargewichtsbereich um 30km kDa

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0856520

Country of ref document: EP

REN Ceased due to non-payment of the annual fee